Abstract
Escherichia coli ST131 has emerged as a global epidemic, multidrug-resistant clone of E. coli causing extra-intestinal infections. It is now highly prevalent among fluoroquinolone-resistant and CTX-M ESBL-producing E. coli isolates worldwide. Humans are likely the primary reservoir of ST131. Factors associated with its acquisition include residence in long-term care facilities and recent receipt of antimicrobial agents. E. coli ST131 causes a wide array of infections ranging from cystitis to life-threatening sepsis. Fluoroquinolones and trimethoprim-sulfamethoxazole are no longer adequate options for empiric therapy when E. coli ST131 is suspected from risk factors and local epidemiology. Expanded-spectrum cephalosporins, piperacillin- tazobactam and carbapenems are options to treat serious non-ESBL-producing E. coli ST131 infections, while carbapenems are indicated for ESBL-producing infections. There is a growing interest in reevaluating oral agents including fosfomycin and pivmecillinam for less serious infections such as uncomplicated cystitis.
| Original language | English |
|---|---|
| Pages (from-to) | 597-609 |
| Number of pages | 13 |
| Journal | Expert Review of Anti-Infective Therapy |
| Volume | 12 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 01-01-2014 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Microbiology
- Microbiology (medical)
- Infectious Diseases
- Virology
Cite this
}
Escherichia coli sequence type 131 : Epidemiology and challenges in treatment. / Qureshi, Zubair A.; Doi, Yohei.
In: Expert Review of Anti-Infective Therapy, Vol. 12, No. 5, 01.01.2014, p. 597-609.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Escherichia coli sequence type 131
T2 - Epidemiology and challenges in treatment
AU - Qureshi, Zubair A.
AU - Doi, Yohei
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Escherichia coli ST131 has emerged as a global epidemic, multidrug-resistant clone of E. coli causing extra-intestinal infections. It is now highly prevalent among fluoroquinolone-resistant and CTX-M ESBL-producing E. coli isolates worldwide. Humans are likely the primary reservoir of ST131. Factors associated with its acquisition include residence in long-term care facilities and recent receipt of antimicrobial agents. E. coli ST131 causes a wide array of infections ranging from cystitis to life-threatening sepsis. Fluoroquinolones and trimethoprim-sulfamethoxazole are no longer adequate options for empiric therapy when E. coli ST131 is suspected from risk factors and local epidemiology. Expanded-spectrum cephalosporins, piperacillin- tazobactam and carbapenems are options to treat serious non-ESBL-producing E. coli ST131 infections, while carbapenems are indicated for ESBL-producing infections. There is a growing interest in reevaluating oral agents including fosfomycin and pivmecillinam for less serious infections such as uncomplicated cystitis.
AB - Escherichia coli ST131 has emerged as a global epidemic, multidrug-resistant clone of E. coli causing extra-intestinal infections. It is now highly prevalent among fluoroquinolone-resistant and CTX-M ESBL-producing E. coli isolates worldwide. Humans are likely the primary reservoir of ST131. Factors associated with its acquisition include residence in long-term care facilities and recent receipt of antimicrobial agents. E. coli ST131 causes a wide array of infections ranging from cystitis to life-threatening sepsis. Fluoroquinolones and trimethoprim-sulfamethoxazole are no longer adequate options for empiric therapy when E. coli ST131 is suspected from risk factors and local epidemiology. Expanded-spectrum cephalosporins, piperacillin- tazobactam and carbapenems are options to treat serious non-ESBL-producing E. coli ST131 infections, while carbapenems are indicated for ESBL-producing infections. There is a growing interest in reevaluating oral agents including fosfomycin and pivmecillinam for less serious infections such as uncomplicated cystitis.
UR - http://www.scopus.com/inward/record.url?scp=84899009317&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899009317&partnerID=8YFLogxK
U2 - 10.1586/14787210.2014.899901
DO - 10.1586/14787210.2014.899901
M3 - Review article
C2 - 24694052
AN - SCOPUS:84899009317
VL - 12
SP - 597
EP - 609
JO - Expert Review of Anti-Infective Therapy
JF - Expert Review of Anti-Infective Therapy
SN - 1478-7210
IS - 5
ER -